Remove 2007 Remove Licensing Remove Pharmaceuticals
article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

Linda Powers, CEO, Northwest Biotherapeutics Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011. She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. I owe so much to Franklin and many others.”

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Next, Saleko highligts how Northumberland and the North East of the UK are recognised for pharmaceutical manufacturing prowess. According to Dr Michelle Fraser, Business Unit Manager, Base Editing at Revvity: “The UK, and especially the Cambridge region, is well known for its pharmaceutical innovation. billion in funding.

Drugs 189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature

The Pharma Data

The Janssen dengue compound discovery program started in 2007. licensed the compound series in 2015, and is continuing to advance the compound into clinical development. 1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats. Janssen Pharmaceutica, N.V.

Virus 52
article thumbnail

BioSpace Movers & Shakers, Nov. 6

The Pharma Data

X4 Pharmaceuticals – Art Taveras was named CSO of Cambridge, Mass.-based Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Most recently, Holland served as Global Head of licensing at Lonza AG.

article thumbnail

EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

The Pharma Data

Eisai submitted a supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway on January 6, 2023. Eisai submitted an application for manufacturing and marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023, in Japan. In the U.S.,

article thumbnail

Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind

The Pharma Data

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. Alzprotect is financed by the XERYS fund (Paris). About Alzprotect.

Drugs 40
article thumbnail

Seladelpar

New Drug Approvals

1] [2] [3] The compound was licensed from Janssen Pharmaceutica NV. [4] 2007 Jul 15;17(14):3855-9. Epub 2007 May 10. 2007.05.007 Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, LLC, 8 Clarke Drive, Cranbury, NJ 08512, USA Scheme 1. Seladelpar cas 851528-79-5 C 21 H 23 F 3 O 5 S, 444.47

FDA 62